These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 37442493)
1. Ashwagandha- Withania somnifera (L.) Dunal as a multipotent neuroprotective remedy for genetically induced motor dysfunction and cellular toxicity in human neurodegenerative disease models of Drosophila. Murthy MN; Shyamala BV J Ethnopharmacol; 2024 Jan; 318(Pt A):116897. PubMed ID: 37442493 [TBL] [Abstract][Full Text] [Related]
2. Withania somnifera (L.) Dunal - Modern perspectives of an ancient Rasayana from Ayurveda. Mukherjee PK; Banerjee S; Biswas S; Das B; Kar A; Katiyar CK J Ethnopharmacol; 2021 Jan; 264():113157. PubMed ID: 32783987 [TBL] [Abstract][Full Text] [Related]
3. Neurodegenerative diseases and Withania somnifera (L.): An update. Dar NJ; Muzamil Ahmad J Ethnopharmacol; 2020 Jun; 256():112769. PubMed ID: 32240781 [TBL] [Abstract][Full Text] [Related]
4. Revisiting the Multifaceted Therapeutic Potential of Withaferin A (WA), a Novel Steroidal Lactone, W-ferinAmax Ashwagandha, from Kumar P; Banik SP; Goel A; Chakraborty S; Bagchi M; Bagchi D J Am Nutr Assoc; 2024 Feb; 43(2):115-130. PubMed ID: 37410676 [No Abstract] [Full Text] [Related]
5. Effects of Ashwagandha (roots of Withania somnifera) on neurodegenerative diseases. Kuboyama T; Tohda C; Komatsu K Biol Pharm Bull; 2014; 37(6):892-7. PubMed ID: 24882401 [TBL] [Abstract][Full Text] [Related]
6. Keeping abreast about ashwagandha in breast cancer. Vashi R; Patel BM; Goyal RK J Ethnopharmacol; 2021 Apr; 269():113759. PubMed ID: 33359916 [TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacokinetic evaluation of Withania somnifera (L.) Dunal root extract in healthy human volunteers: A non-randomized, single dose study utilizing UHPLC-MS/MS analysis. Vaidya VG; Naik NN; Ganu G; Parmar V; Jagtap S; Saste G; Bhatt A; Mulay V; Girme A; Modi SJ; Hingorani L J Ethnopharmacol; 2024 Mar; 322():117603. PubMed ID: 38122911 [TBL] [Abstract][Full Text] [Related]
8. Angiotensin converting enzyme inhibitor captopril prevents neuronal overexpression of amyloid-beta and alpha-synuclein in Drosophila melanogaster genetic models of neurodegenerative diseases. Ishola I; Afolayan O; Badru A; Olubodun-Obadun T; John N; Adeyemi O Niger J Physiol Sci; 2022 Jun; 37(1):21-28. PubMed ID: 35947848 [TBL] [Abstract][Full Text] [Related]
9. Scientific basis for the use of Indian ayurvedic medicinal plants in the treatment of neurodegenerative disorders: ashwagandha. Ven Murthy MR; Ranjekar PK; Ramassamy C; Deshpande M Cent Nerv Syst Agents Med Chem; 2010 Sep; 10(3):238-46. PubMed ID: 20528765 [TBL] [Abstract][Full Text] [Related]
10. Rational use of Ashwagandha in Ayurveda (Traditional Indian Medicine) for health and healing. Joshi VK; Joshi A J Ethnopharmacol; 2021 Aug; 276():114101. PubMed ID: 33831467 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Ashwagandha (Withania somnifera (L.) Dunal) Root Extract in Improving Memory and Cognitive Functions. Choudhary D; Bhattacharyya S; Bose S J Diet Suppl; 2017 Nov; 14(6):599-612. PubMed ID: 28471731 [TBL] [Abstract][Full Text] [Related]
12. Functional and Morphological Correlates in the Drosophila LRRK2 loss-of-function Model of Parkinson's Disease: Drug Effects of Withania somnifera (Dunal) Administration. De Rose F; Marotta R; Poddighe S; Talani G; Catelani T; Setzu MD; Solla P; Marrosu F; Sanna E; Kasture S; Acquas E; Liscia A PLoS One; 2016; 11(1):e0146140. PubMed ID: 26727265 [TBL] [Abstract][Full Text] [Related]
13. A double-blind, randomized, placebo-controlled trial on the effect of Ashwagandha (Withania somnifera dunal.) root extract in improving cardiorespiratory endurance and recovery in healthy athletic adults. Tiwari S; Gupta SK; Pathak AK J Ethnopharmacol; 2021 May; 272():113929. PubMed ID: 33600918 [TBL] [Abstract][Full Text] [Related]
14. Withania somnifera (L.) Dunal (Ashwagandha): A comprehensive review on ethnopharmacology, pharmacotherapeutics, biomedicinal and toxicological aspects. Paul S; Chakraborty S; Anand U; Dey S; Nandy S; Ghorai M; Saha SC; Patil MT; Kandimalla R; Proćków J; Dey A Biomed Pharmacother; 2021 Nov; 143():112175. PubMed ID: 34649336 [TBL] [Abstract][Full Text] [Related]
15. In vitro protective effects of Withania somnifera (L.) dunal root extract against hydrogen peroxide and β-amyloid(1-42)-induced cytotoxicity in differentiated PC12 cells. Kumar S; Seal CJ; Howes MJ; Kite GC; Okello EJ Phytother Res; 2010 Oct; 24(10):1567-74. PubMed ID: 20680931 [TBL] [Abstract][Full Text] [Related]
16. E46K mutant α-synuclein is more degradation resistant and exhibits greater toxic effects than wild-type α-synuclein in Drosophila models of Parkinson's disease. Sakai R; Suzuki M; Ueyama M; Takeuchi T; Minakawa EN; Hayakawa H; Baba K; Mochizuki H; Nagai Y PLoS One; 2019; 14(6):e0218261. PubMed ID: 31242217 [TBL] [Abstract][Full Text] [Related]
18. Aqueous extract from the Withania somnifera leaves as a potential anti-neuroinflammatory agent: a mechanistic study. Gupta M; Kaur G J Neuroinflammation; 2016 Aug; 13(1):193. PubMed ID: 27550017 [TBL] [Abstract][Full Text] [Related]